Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.63 |
| ▸ | ACACA | Q13085 | 2/20 | 0.63 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.55 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13455191 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL1878720 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL1653320 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL1878721 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL14047057 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL14520017 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL12152345 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13420256 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13801861 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL11408854 | 1.00 | ACLY (0.63) | ACLYACACAPTPN11HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301460-B9 | METHOD FOR PREPARING A FATTY SUBSTANCE ESTER AND USE THEREOF IN PHARMACEUTICS, COSMETICS OR FOOD INDUSTRY | EXPANSCIENCE LAB (FR) | 2009-03-11 | — | — | EP | claimed |
| EP-1301460-B1 | METHOD FOR PREPARING A FATTY SUBSTANCE ESTER AND USE THEREOF IN PHARMACEUTICS, COSMETICS OR FOOD INDUSTRY | EXPANSCIENCE LAB (FR) | 2008-08-06 | — | — | EP | claimed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | claimed |
| CN-107582899-B | Mongolian medicine for clearing heat and stopping bleeding and its preparing process | 内蒙古民族大学附属医院 | 2021-01-15 | — | — | CN | disclosed |
| CN-109731026-A | A kind of externally used Mongolian medicine of set a broken bone and preparation method thereof | 内蒙古民族大学附属医院 | 2019-05-10 | — | — | CN | disclosed |
| CN-109394824-A | A kind of anaesthetic of bone-setting pain stopping and preparation method thereof | 内蒙古民族大学附属医院 | 2019-03-01 | — | — | CN | disclosed |
| EP-3120854-A1 | CYCLOARTENOL-CONTAINING COMPOSITION | Kao Corporation (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20170014430-A1 | Cycloartenol-Containing Composition | KAO CORPORATION (JP) | 2017-01-19 | — | — | US | disclosed |
| CN-106261429-A | A kind of clear and rich beverage composition and preparation method thereof | 陈桂玲 | 2017-01-04 | — | — | CN | disclosed |
| US-9200029-B2 | Process for production of triterpene alcohol | KAO CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2607372-B1 | PROCESS FOR PRODUCTION OF TRITERPENE ALCOHOL | KAO CORP (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2262516-A2 | COMPOSITION CONTAINING CAPSICUM FOR TREATING A SKIN DISORDER | Rezai-Fard, Ali (GB) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010082689-A2 | GIP-INCREASE INHIBITOR | KAO CORPORATION (JP) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009090394-A2 | COMPOSITION FOR TREATING A SKIN DISORDER | REZAI-FARD ALI (GB) | 2009-07-23 | — | — | WO | disclosed |
| US-7511010-B2 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration | LABORATOIRES EXPANSCIENCE (FR) | 2009-03-31 | — | — | US | disclosed |
| US-20080221017-A1 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration | LABORATOIRES EXPANSCIENCE | 2008-09-11 | — | — | US | disclosed |
| US-6828451-B2 | Fatty substance is esterified with alcohol selected from sterols, stanols, 4-methylsterols and their hydrogenated homologs, triterpene alcohols, and mixtures, in presence of solid lanthanide metal oxide catalyst | LABORATOIRES EXPANSCIENCE (FR) | 2004-12-07 | — | — | US | disclosed |
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | LABORATOIRES EXPANSCIENCE (FR) | 2004-04-08 | — | — | US | disclosed |
| US-5869708-A | Process for the isolation of oryzanols from crude dark acid oil (rice bran) | COUNCIL FOR SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1999-02-09 | — | — | US | disclosed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | MMP1, MMP2, MMP13 | ACLY 3600/4885ACACA 964/4885PTPN11 1380/4885 |
| US-20080221017-A1 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration | MMP1, MMP13, MMP2 | ACLY 3624/4885ACACA 865/4885PTPN11 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.